A PHASE-II STUDY OF SULOFENUR, A NOVEL SULFONYLUREA, IN RECURRENT EPITHELIAL OVARIAN-CANCER

被引：16

作者：

OBRIEN, MER ^{[1
]}

HARDY, J ^{[1
]}

TAN, S ^{[1
]}

WALLING, J ^{[1
]}

PETERS, B ^{[1
]}

HATTY, S ^{[1
]}

WILTSHAW, E ^{[1
]}

机构：

[1] LILLY RES CTR LTD,WINDLESHAM GU20 6PH,SURREY,ENGLAND

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1992年 / 30卷 / 03期

关键词：

D O I：

10.1007/BF00686324

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A total of 16 patients with recurrent epithelial ovarian cancer were treated with sulofenur (LY 186641), a novel oral sulfonylurea. All subjects had received previous chemotherapy. Anaemia occurred in all 16 patients, 14 of whom required a blood transfusion, and 2/16 patients received methylene blue for breathlessness due to methaemaglobinaemia. Treatment was discontinued in 2/16 cases due to rising liver enzyme values, which reverted to normal on cessation of the drug. There was no nausea or alopecia. Only two minor responses were seen. Plasma drug levels were insufficient to result in anti-tumour activity as extrapolated from animal data. Further studies that attempt to increase the bioavailability and improve the therapeutic index are warranted.

引用

页码：245 / 248

页数：4

共 8 条

[1]

ARMAND JP, 1989, 6TH P NCI EORTC S NE

[2] RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].